Imatinib Cipla (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing phosphorylation of downstream signaling proteins. This blockade stops proliferative signals in malignant cells, leading to apoptosis while largely sparing normal cells that do not rely on these kinases.

The dose of Imatinib Cipla is individualized by the treating physician based on the specific indication, disease stage, patient weight, renal and hepatic function, and response to therapy. Only a qualified prescriber can determine the appropriate regimen.

Safety data for imatinib in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Imatinib Cipla, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard first‑line option for CML and GIST. Newer agents such as dasatinib or nilotinib may offer potency advantages in resistant disease, but Imatinib’s long‑term safety profile, extensive clinical experience and lower cost make it a preferred choice for many patients.

Imatinib Cipla tablets should be stored at room temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture, heat and direct sunlight to maintain product stability throughout its shelf life.

Imatinib Cipla is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the prescribing physician’s instructions regarding timing and any necessary dietary considerations.

Serious adverse events include severe liver toxicity, marked neutropenia or thrombocytopenia, cardiac failure, pulmonary arterial hypertension, and rare severe skin reactions such as Stevens‑Johnson syndrome. Prompt medical evaluation is required if any of these symptoms develop.

Imatinib Cipla is contraindicated in individuals with known hypersensitivity to imatinib or any of its excipients. Caution is advised for patients with pre‑existing liver disease, severe cardiac dysfunction, or uncontrolled infections. The drug should be avoided in pregnant women unless absolutely necessary.